Citations

Clear

4510 citation(s) found for "Scott, L".

A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk
Eriksson, Mikael , Czene, K, Scott, C, Stoddard, Shawn, Smith, Hugh, Hall, Per , Vachon, C, Scott, Christopher G. , Vachon, Celine M. , Czene, Kamila , Czene, Kamila , Scott, Christopher , Vachon, Celine M. , Hall, Per N , Eriksson, Mikael , Stoddard, Shawn M.

Mayo Clinic

Science Translational Medicine | May 20, 2026 | Volume: 18 | Issue: 850 | Pages: No page available

10.1126/scitranslmed.ady7414 | PMID 42160452 Get It

Image-derived artificial intelligence (AI) risk models have shown promise in short-term risk assessment for improving breast cancer (BC) screening. No image-derived long-term AI risk model for primary prevention has been developed and externally validated. Individuals aged 31 to 94 years were recruited between 2010 and 2020 in two population-based case cohorts (Olmsted County, Minnesota, US, and KARMA, Sweden) and one hospital-based case-control study (EMBED, Atlanta, US). Median follow-up in the case cohorts was 10 years, with BCs diagnosed through June 2022. Additional validation was performed in EMBED with 3-year follow-up. An AI risk model was developed in Sweden, and we report independent validation in Olmsted/KARMA/EMBED. Absolute 10-year risks were estimated at study entry. Time-dependent discriminatory performance [AUC( t )] and expected-to-observed events (E/O) were estimated. Comparisons were performed with clinical risk tools and the image-based Mirai tool. Across Olmsted/KARMA, 8696 individuals (mean age, 54.4±10.6) and 1633 individuals with incident BC (mean age, 57.0±10.6) were included. Average 10-year risks were 3.83 and 3.14%, and E/O ratios were 0.99 and 0.99. Ten-year AUC( t ) for invasive BCs were 0.72 in Olmsted and 0.72 in KARMA. Similar discriminatory results were observed in EMBED. Our AI risk tool performed significantly better than Mirai in Olmsted/KARMA/EMBED. In KARMA, in the top 10% of high-risk individuals, the AI risk tool predicted 33% of BCs compared with 23%/20%/24% predicted by Tyrer-Cuzick-v8/BCSC-v3/Mirai (all P < 0.01). The 10-year image-derived AI risk model showed significantly higher performance than clinical risk models and Mirai in diverse populations, supporting its clinical potential for primary prevention.
Cross‐Vendor Validation of Proton Density Fat Fraction and T 1 Mapping Using a Combined Proton Density Fat Fraction—
Starekova, Jitka , Weingärtner, Sebastian , Rutkowski, David , Fullerton, Garrett , Bae, Won C. , Do, Hung P. , Madhuranthakam, Ananth J. , Lin, S. , Serai, Suraj D., Brittain, Jean H. , Hernando, D, Rutkowski, David R , Fullerton, Garrett C , Lin, Sheng Qing , Serai, Suraj D , Yokoo, Takeshi , Reeder, Scott B. , Brittain, Jean H , Hernando, Diego , Do, Hung Phi , Malis, Vadim , Serai, Suraj D. , Yokoo, Takeshi

Mayo Clinic

Journal of Magnetic Resonance Imaging | May 20, 2026 | Volume: 64 | Issue: 2 | Pages: 482-492

10.1002/jmri.70344 | PMID 42159302 Get It

ABSTRACT Background In chronic liver disease, fat and fibroinflammatory changes often coexist. However, their biomarkers, proton density fat fraction (PDFF) and T 1 , are typically assessed separately. Their reproducibility under mutual confounding remains unclear. Purpose To assess multicenter, multi‐vendor reproducibility of confounder‐corrected chemical shift‐encoded (CSE)‐MRI‐based PDFF mapping and MOLLI‐based T 1 mapping using a combined PDFF‐T 1 phantom. Study Type Prospective phantom study. Phantom Commercial PDFF‐T 1 Phantom (Model 725) with varying PDFF (0%–30%) and T 1 (200–1400 ms) values. Field Strength/Sequence 1.5 T and 3 T multi‐echo, three‐dimensional spoiled‐gradient‐echo (SGRE) sequence for PDFF mapping, and MOLLI sequence (5(3)3 acquisition scheme) using two‐dimensional SGRE readouts for T 1 mapping across four centers and vendors. Assessment PDFF and T 1 maps were acquired using standardized protocols. PDFF maps were reconstructed locally, while T 1 maps were generated using a centralized algorithm. All maps were quantitatively analyzed by a single radiologist using standardized region‐of‐interest placement. Phantom temporal stability was assessed at one center across five sessions over 9 months (baseline, retest, 1 week, 6 and 9 months). Statistical Tests Intraclass correlation coefficients (ICC), reproducibility coefficients (RDC), and linear regression analysis were used. A p value < 0.05 was considered statistically significant. Results PDFF showed overall excellent reproducibility (ICC = 0.987, RDC = 3.7%), with increased variability at higher T 1 values (RDC up to 7.9% at T 1 = 1400 ms). T 1 mapping showed good reproducibility in the absence of fat (RDC 16–161 ms at PDFF = 0%), but moderate to poor reproducibility in the presence of fat, with RDC increasing up to 1553 ms at PDFF 30%. Temporal stability was excellent ICC ≥ 0.998 for both PDFF and T 1 , and RDC of 1.1%–1.3% for PDFF and 52–57 ms for T 1 . Data Conclusion This phantom study demonstrated high reproducibility of PDFF, whereas T 1 reproducibility deteriorated at higher fat and T 1 levels, underscoring the need for fat‐corrected T 1 mapping for reliable assessment of fibroinflammatory changes. Evidence Level N/A. Technical Efficacy Stage 1.
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-
Bansal, Ajay, Stoffel, Elena M., Lim, Ramona , Burke, Carol, Hall, Michael J., Singh, Aparajita , Boardman, Lisa A., Samadder, Niloy Jewel, Ballestar, Veroushka, Muller, Charles, Scott, Aaron J. , Xu, Yanfei , Eickhoff, Jens, Meredith, Hyun, Aquila, Lanni , Szabó, Éva , Della’Zanna, Gary , Bengtson, Lisa, Schlom, Jeffrey, Donahue, Renee N., Horn, Lucas A., Palena, Claudia, Gulley, James L., Samaddar, Sohini, Moore, Dennis F., Sharma, Parth, Madan, Rashna , Hurley, Karen, Soon‐Shiong, Patrick , Gabitzsch, Elizabeth, Sender, Lennie, Brenner, Dean, Schuetze, Scott, Djuric, Zora, Barroilhet, L. E., Thompson, Patricia, Bauman, Julie, Khan, Seema, Vilar, Eduardo, Szabo, Eva , Stoffel, Elena M. , Stanich, Peter P. , Patel, Swati , Burke, Carol A. , Hall, Michael J. , Muller, Charles , Benante, Kelly A. , Eickhoff, Jens C. , Zaborek, Jen , Umar, Asad , Richmond, Ellen S. , Schlom, Jeffrey , Donahue, Renee Nicole , Toney, Nicole J. , Palena, Claudia , Gulley, James L , Moore, Dennis F., Djurić, Zora , Barroilhet, Lisa , Vilar, Eduardo

Mayo Clinic

Frontiers in Immunology | May 19, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1809281 | PMID 42238576 Get It

Introduction Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers. Methods In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity. Results All 20 SP participants (median age 57.5 (range 42–75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual. Discussion In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. Clinical Trial Registration https://clinicaltrials.gov/study/ , identifier NCT05419011.
Cognitive dispersion profiles and prediction of cognitive change in early‐onset dementias: Results from LEADS
Hammers, Dustin B., Foster, Elodie, Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra, Joie, Renaud La, Beckett, Laurel, Gao, Sujuan, Vemuri, Prashanthi, Nudelman, Kelly N., Kirby, Kala, Dage, Jeffrey L., Aisen, Paul, Atri, Alireza, Clark, David G., Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalski, Emily, Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Dickerson, Bradford C., Rabinovici, Gil D., Carrillo, Maria C., Apostolova, Liana G., Joie, Renaud La , La Joie, Renaud , Hammers, Dustin B , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra , Beckett, Laurel , Gao, Sujuan , Vemuri, Prashanthi , Nudelman, Kelly , Kirby, Kala, Dage, Jeffrey L. , Aisen, Paul , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Rabinovici, Gil D. , Carrillo, María C. , Apostolova, Liana G.

Mayo Clinic

Alzheimer's & Dementia | May 19, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71492 | PMID 42151732 Get It

Abstract INTRODUCTION Research into cognitive dispersion – a cognitive process score measuring the intra‐individual variability (IIV) across a single testing session – suggests utility in neurodegenerative populations. Given widespread deficits observed in sporadic early‐onset Alzheimer's disease (EOAD), however, it is unclear if examining cognitive dispersion shows benefit in this condition. METHODS A total of 309 participants (188 amyloid‐positive EOAD, 43 amyloid‐negative early‐onset dementia [EOnonAD], 78 cognitively normal [CN]) completed neuropsychological testing twice over 12 months. Dispersion‐related differences among groups were assessed, as was cognitive dispersion's capacity to predict domain‐specific cognitive trajectories, and its convergence with imaging biomarkers. RESULTS EOAD participants displayed higher cognitive dispersion than EOnonAD participants, and associations with EOAD‐specific biomarkers. Additionally, cognitive dispersion was associated with 12‐month reliable change across several cognitive domains. DISCUSSION These preliminary results examine cognitive dispersion in sporadic EOAD. When used with baseline cognitive performance, cognitive dispersion measures may enrich future clinical trials in EOAD by enhancing treatment monitoring over time.
C47-02 Factors Associated With Acute Cellular Rejection Within 1-year Post-lung Transplantation: A Single Center Cross-sectional Study
Khan, A, Balasubramanian, P, Postell, A M, Soto-Arenall, M W, Bag, R, Narula, T, Alvarez, F G, Baz, M A, Makey, I A, Scott, C, Saikus, C E, Mathew, T, Haney, J, Shah, S Z, Balasubramanian, P., Postell, A., Soto‐Arenall, Matthew, Bag, Remzi , Narula, T., Alvarez, Francisco , Baz, Maher A. , Makey, Ian A. , Scott, C, Haney, John C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6614 Get It

Abstract Rationale Acute cellular rejection (ACR) within first-year post-lung transplantation has important implications for prognosis. Calcineurin inhibitors (CNI), including tacrolimus or cyclosporine, along with cell cycle inhibitors (CCI) and steroids, remain the standard immunosuppression regimen post-transplant. Although tacrolimus is used as the primary CNI, target therapeutic levels vary across recipients due to adverse effects and tolerability, sometimes requiring switching over to Cyclosporine. We hypothesized that ACR within the first year is associated with switching CNI from Tacrolimus to Cyclosporine. Methods We performed a cross-sectional study of 255 adult lung transplant recipients between June 2019 to November 2024 at Mayo Clinic, Florida. Demographics, induction regimens, CNI type and their levels (average low and high levels) were compared between the 2 groups. The institutional maintenance immunosuppression regimen is Tacrolimus, Mycophenolate Mofetil (MMF) and prednisone, but could be switched to Cyclosporine if the previous regimen is not tolerated. The primary outcome was ACR &lt;1 year diagnosed based on biopsy and/or clinical criteria. Comparisons between groups were performed using Chi-Square test for categorical variables and t-test or Wilcoxon Rank sum test for continuous variables. Multivariable regression analysis was performed with ACR &lt;1 year as the outcome to adjust for the confounders. Results Our cohort included 255 lung transplant recipients with median age of 63 years, 61% Male, 84% Caucasians, 88% bilateral lung transplant (Further details elucidated in Table 1). A total of 173 (67%) out of 255 patients had ACR &lt;1 year. The group with ACR &lt; 1 year had higher proportion of Interstitial Lung Disease (ILD) (81% vs 68%, p = 0.044), use of Basiliximab for induction (70% vs 55%, p = 0.018), and cyclosporine instead of tacrolimus (23% vs 11%, p = 0.027). Group with ACR &lt;1 year also had higher Antibody Mediated Rejection (AMR) &lt; 1year (15% vs 6.1%, p = 0.041) and higher CLAD (BOS 0p-3: 43% vs 25.6%, p = 0.033) compared to the group without ACR &lt; 1 year (Table 1.1). Multivariate regression analysis showed ILD (adjusted odds ratio, aOR 2.84, 95% CI 1.31 - 6.27, p = 0.008) and use of cyclosporine (aOR 2.55, 95% CI 1.07 - 6.78, p = 0.034) as independent predictors of ACR &lt; 1 year (Table 2). Conclusions The presence of ACR &lt; 1 year was associated with the use of Cyclosporine over Tacrolimus as a maintenance regimen. Also, ACR &lt; 1year was associated with higher AMR and CLAD. Further prospective studies are needed to study this long-term given its significant prognostic implications. This abstract is funded by: Not Applicable
A66-16 Efficacy of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Disease With Normal Resting Hemodynamics: A Systematic Review and Meta-analysis
Saeed, A M, Hmeedan, A, Karam, A M, Najjar, H, Najjar, S, Abdallah, T, Bisher, F B, Ibrahim, R, Rmileh, A Abu, Swanson, K L, Cartin, C, Scott, R L, Nabhan, A, Hamad, A, Alqalyoobi, S, Heresi, G A, Alshaer, A, Azar, J, Swanson, Karen L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5590 Get It

Abstract Rationale Chronic thromboembolic disease (CTED), which is the result of persistent pulmonary vascular obstruction despite 3 months of anticoagulation, can present with significant functional limitations and exercise intolerance despite normal resting hemodynamics. These patients may experience functional impairment due to exercise-induced pulmonary hypertension, impaired stroke volume augmentation with exercise, ventilatory inefficiency, and/or preload insufficiency. Such exercise-induced pathophysiological abnormalities can significantly impair quality of life and contribute to poor long-term outcomes. Although balloon pulmonary angioplasty (BPA) has shown benefit in patients with chronic thromboembolic pulmonary hypertension (CTEPH), its role in CTED patients with normal resting hemodynamics remains uncertain. This systematic review and meta-analysis evaluated the efficacy of BPA in this population. Methods A systematic search of PubMed, Cochrane, Embase, and Scopus was performed from inception through March 1, 2025. A total of 763 studies were screened, of which 42 full-text articles were assessed: six met the inclusion criteria (four retrospective, two prospective), comprising 98 patients. Results Across the included studies, baseline mean values were 20.81 +/- 3.62 mmHg for mean pulmonary arterial pressure (mPAP), 3.49 +/- 1.42 Wood units for pulmonary vascular resistance (PVR), and 405.72 +/- 108.40 m for the 6-minute walk distance (6MWD). Balloon Pulmonary Angioplasty (BPA) was consistently associated with significant improvements in hemodynamic and functional outcomes; BPA reduced mPAP by 3.40 mmHg and PVR by 0.90 WU, while increasing 6MWD by 31.90 m. These changes were also statistically robust across studies, with pooled standardized mean changes (SMC) of -0.88 for mPAP (95% CI, -1.10 to -0.67; P &lt; .05), -0.68 for PVR (95% CI, -0.87 to -0.49; P &lt; .05), and 0.29 for 6MWD (95% CI, 0.13 to 0.45; P &lt; .05). Study-level effect sizes for 6MWD ranged from 0.19 to 0.54 (Figure 1A). Functional improvements were further demonstrated by shifts in NYHA class distribution (Figure 1B). Conclusion BPA was associated with meaningful reductions in mPAP and PVR and significant improvements in functional capacity among patients with CTED. These results indicate that BPA could be an effective treatment for certain patients with CTED, though more research is necessary. This abstract is funded by: None
A66-15 Efficacy of Pulmonary Endarterectomy in Patients With Chronic Thromboembolic Disease With Normal Resting Hemodynamics: A Systematic Review and Meta-analysis
Hmeedan, A, Karam, A M, Najjar, H, Saeed, A M, Alshaer, A, Asad, T, Hamad, A, Nabhan, A, Najjar, S, Abdelhafez, M, Abdallah, T, Bisher, F B, Ibrahim, R, Abdelnabi, M, Scott, R L, Cartin-Ceba, R, Swanson, K L, Rmilah, A Abu, Alqalyoobi, S, Heresi, G A, Azar, J, Asad, Thekrayat, Najjar, S, Abdelnabi, Mahmoud , Cartin‐Ceba, Rodrigo , Swanson, Karen L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5589 Get It

Abstract Rationale Chronic thromboembolic disease (CTED) is characterized by persistent pulmonary vascular obstruction due to unresolved thromboemboli despite at least three months of anticoagulation. Although resting hemodynamics often remain normal, affected patients frequently develop functional limitation due to exercise-induced pulmonary hypertension, ventilatory inefficiency, limited stroke volume augmentation, or preload insufficiency. Such exercise-induced pathophysiological dysregulation can significantly impair quality of life and contribute to poor long-term outcomes. Pulmonary endarterectomy (PEA) is an established treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), offering significant improvements in hemodynamics and survival. Its role in CTED, however, remains unclear. While CTED has traditionally been managed with anticoagulation and supportive therapy, emerging evidence suggests PEA may provide symptomatic and functional benefit in selected CTED patients. Given the ongoing uncertainty regarding the role of PEA in CTED, we performed a systematic review and meta-analysis to define its safety profile and clinical efficacy in this patient subset. Methods A systematic search of PubMed, Cochrane, Embase, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar was conducted from database inception to March 1, 2025. Of 2,244 records screened, 34 full-text articles were assessed, and seven met the inclusion criteria. Results Across the included studies, the pooled baseline mean values were 20.48 ± 3.03 mm Hg for mean pulmonary arterial pressure (mPAP), 2.83 ± 1.11 Wood units for pulmonary vascular resistance (PVR), and 397 ± 100.08 m for the 6-minute walk distance (6MWD). Pulmonary Endarterectomy (PEA) was consistently associated with significant improvements in hemodynamic and functional outcomes; PEA reduced mPAP by 3.58 mmHg (pooled Standardized Mean Change (SMC)=-1.03; 95% CI, -1.23 to -0.83; P &lt; .05), PVR by 0.86 Woods units (pooled SMC=-0.86; 95% CI, -1.05 to -0.67; P &lt; .05), while, conversely, increased 6MWD by 37.49 m (pooled SMC, 0.49; 95% CI, 0.32 to 0.67; P &lt; .05). Study-level effect sizes for 6MWD ranged from 0.21 to 1.47 (Figure 1A). This clinical improvement is further reflected in the enhancement of the NYHA functional class, as illustrated in Figure 1B. Conclusion PEA was associated with significant reductions in mPAP and PVR, as well as a considerable improvement in functional capacity in patients with CTED, with robust results across multiple tests for bias, influence, and sensitivity analyses. These findings support PEA as a viable therapeutic option for selected patients with CTED, although further research is warranted. This abstract is funded by: None
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Rourk, Katelyn S. , Baratz, Hannah , Eyassu, Daniel G. , Price, Katharine A., Moore, Eric J. , Patel, Samir H., Hinni, Michael L., Neben-Wittich, M.A. , Garces, Yolanda I. , McGee, L.A. , Wilson, Jessica, Rwigema, Jean-Claude M., Chintakuntlawar, Ashish V., Mohammadi, Homan , Price, Daniel L., Janus, Jeffrey R. , Garcia, Joaquin J., Foote, Robert L., Tasche, Kendall K. , Ma, Daniel J., Hidalgo, Cecelia M, Baratz, Hannah Q , Neben-Wittich, Michelle A, Lester, Scott C. , Holtzman, Adam L. , Rwigema, Jean‐Claude M. , Chintakuntlawar, Ashish V. , Price, Daniel L. , García, Joaquín J., Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda X. , Routman, David M.

Mayo Clinic

JAMA Network Open | May 18, 2026 | Volume: 9 | Issue: 5 | Pages: e2612837

10.1001/jamanetworkopen.2026.12837 | PMID 42149594 Get It

Importance Standard adjuvant therapy for human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is radiation therapy 60 Gy with or without cisplatin delivered in 30 fractions during 6 weeks. A phase 3 randomized clinical trial demonstrated decreased toxic effects and improved patient-reported outcomes with de-escalated adjuvant radiation therapy (DART) compared with standard therapy; however, outcomes for patients treated in the clinical practice setting following trial adoption remain unknown. Objective To compare characteristics and oncologic outcomes of patients treated with DART during clinical trials (on study) and in clinical practice settings (off study) and report progression-free survival (PFS) by risk category. Design, Setting, and Participants This retrospective cohort study included patients treated with DART in the MC1273 and MC1675 trials and in clinical practice after study completion at a multisite tertiary care center. Patients with surgically resectable HPV-OPSCC who underwent margin-negative resection between August 20, 2013, and March 21, 2023, and were treated with DART were included in the analysis. Those with prior head and neck cancer, pT0 or pT4 disease, unknown HPV status, metastatic disease at presentation, synchronous primary tumors, induction chemotherapy, or treatment at an outside institution were excluded. Data were analyzed from July 1, 2024, to July 18, 2025. Interventions DART consisting of 30 to 36 Gy in 1.5- to 1.8-Gy fractions twice daily with docetaxel 15 mg/m 2 on days 1 and 8. Main Outcomes and Measures Progression-free survival as measured via Kaplan-Meier analysis. Results A total of 282 patients were included in the analysis: 176 (62.4%) in the on-study group and 106 (37.6%) in the off-study group (252 [89.4%] male; mean [SD] age, 59.1 [9.3] years). Both groups were predominantly male (157 [89.2%] and 95 [89.6%], respectively) and consisted mostly of never smokers (118 [67.0%] and 62 [58.5%], respectively). Pathologic features were similar between groups except for nodal stage (pN1: 155 [88.1%] on study vs 102 [96.2%] off study; pN2: 21 [11.9%] on study vs 4 [3.8%] off study; P = .02). The median follow-up times were 5.2 years (95% CI, 5.2-5.8 years) in the on-study group and 2.2 years (95% CI, 1.9-2.4 years) in the off-study group. Two-year PFS was similar (93% [95% CI, 88%-97%] on study vs 93% [95% CI, 88%-99%] off study). For patients with pN1 and no extranodal extension (ENE), 2- and 5-year PFS were 97% (95% CI, 93%-100%) and 96% (95% CI, 92%-100%), respectively. Patients with pN1 and ENE had a 2- and 5-year PFS of 93% (95% CI, 89%-98%) and 87% (95% CI, 81%-94%), respectively. Conclusions and Relevance In this retrospective cohort study of patients receiving DART on and off study, oncologic outcomes were similar between the 2 groups. Fewer patients with pN2 received DART off study, given the interim results of MC1675. Patients with pN1 and no ENE treated with DART had excellent 2- and 5-year PFS, supporting DART as a compelling treatment option in well-selected patients. An additional study that is currently underway will evaluate biomarker risk-stratified treatment of patients with pN1 and ENE receiving DART.
Design of a next‐generation conventional scintillator x‐ray detector: Improved spatial resolution and fill factor
Hsieh, Scott S., Hsieh, Scott S.

Mayo Clinic

Medical Physics | May 16, 2026 | Volume: 53 | Issue: 5 | Pages: No page available

10.1002/mp.70486 | PMID 42142394 Get It

Abstract Background The most compelling advantage that photon counting detectors (PCDs) currently have over energy integrating detectors (EIDs) for CT applications may be their improved spatial resolution. However, PCDs are difficult to manufacture. Next‐generation EIDs using conventional scintillator sensors could be easier to mass produce, but their spatial resolution is thought to be limited by fill factor considerations. Specifically, each EID pixel comprises a block of scintillator surrounded by inactive, optically reflective septa. The minimum width of optically reflective septa is ∼0.1 mm, and unless this is shrunk, decreases in pixel pitch inevitably cause an increasing fraction of dead space. Purpose To propose a modified system geometry in which the detector pixels are tilted by a few degrees, such that rays that are incident on reflective septa would later encounter scintillator. Because reflective septa are nearly transparent to x‐rays compared to scintillator, this geometry restores much of the lost fill factor. Methods Tilting can be achieved in several different ways. We discuss three implementation options: individual detector modules may be tilted, with gaps between modules that are seamless from the perspective of the x‐ray source; the whole detector can be arranged to point towards a “false” focal spot that is offset slightly from the true focal spot; the scintillator wafer can structured differently, e.g. by sawing it at an angle. The pros and cons of each option are discussed. Tilting introduces blurring, but a smaller pixel size improves resolution, and the combination of both improves both resolution and fill factor. We used Monte Carlo simulations to compare a conventional detector with 1.0 mm, 0.75, or 0.5 mm pixel pitch to a tilted detector with 0.5 mm pixel pitch. We assumed negligible optical crosstalk and electronic noise, that the scintillator was 1.5 mm thick with attenuation similar to gadolinium oxysulfide, that the reflective septa was 0.1 mm wide at standard resolution or 0.08 mm at higher resolutions and composed of a low‐attenuating polymer similar to acrylic infused with 20% titanium content. We also compared this to a simple model of a CdTe detector with 1.6 mm thickness, 0.3 mm pixel pitch, and Gaussian charge sharing. Results Tilt increases the aperture of the pixel in an energy‐dependent fashion. With a 1D ASG (85% fill factor) and at 120 kVp, the detection efficiencies (DQE(0)) of a conventional detector at 1.0 mm, conventional detector at 0.5 mm pixel pitch, CdTe detector, and tilted detector at 0.5 mm pixel pitch are 65%, 55%, 66%, and 64%, respectively. With a sparse 2D ASG (1.5 × 3.0 mm openings, 86% fill factor), the DQE(0) of a tilted detector with 0.75 mm is 69%. The DQE(0) of all detectors decreases at higher energy because of punch‐through. Conclusions By tilting detector modules a few degrees, energy‐integrating detectors can provide increases in spatial resolution without the expected losses in fill factor. This architecture could bring the resolution improvements associated with photon counting CT into the domain of energy‐integrating detectors equipped with conventional scintillator sensors.
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas
Gottesdiener, Lee , Li, Yixuan, Greenwood‐Quaintance, Kerryl E. , Komarow, Lauren, Arias, César A. , Cober, Eric, Herc, Erica , Kaye, Keith S., Huskins, W. Charles, Figueroa, Jairo, Vilchez, Samuel, Leroi, Marcel, Rioseco, María L., Munita, Jose M., Reyes, Jinnethe , Kreiswirth, Barry N. , Hill, Carol, Baum, Keri, Chambers, Henry F., Fowler, Vance G. , Doi, Yohei, Satlin, Michael J., Group, on behalf of the Antibacterial Resistance Leadership, Munita, José M. , Fries, Bettina C , Reyes, Jinnethe , Chen, Liang , Kreiswirth, Barry N , Villegas, Maria Virginia , Paterson, David L. , Bonomo, Robert A , Fowler, Vance G. , Patel, Robin , van Duin, David , Satlin, Michael J , Evans, Scott R , Munita, Jose M , Komarow, Lauren , Arias, César A. , Cober, Eric , Kaye, Keith S. , Huskins, W. Charles , Fries, Bettina C. , Leroi, Marcel , McCarty, Todd P , Rioseco, María Luisa, Stryjewski, Martín E. , Hill, Carol , Baum, Keri, Villegas, María Virginia , Bonomo, Robert A. , Chambers, Henry F. , Patel, Robin , Doi, Yohei , Satlin, Michael J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 15, 2026 | Volume: 70 | Issue: 6 | Pages: No page available

10.1128/aac.00388-25 | PMID 42138639 Get It

ABSTRACT Novel β-lactam/β-lactamase inhibitors (βL/βLIs) are important therapies for carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, the global extent of resistance to these agents and the impact of resistance on patient outcomes are unclear. We therefore evaluated patients with CRPA isolates at 35 hospitals (nine countries) from December 2018 to November 2019. Antimicrobial susceptibility testing was performed at a central laboratory by agar dilution for ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) and by broth microdilution for imipenem-relebactam (I/R). Characteristics and outcomes, including desirability of outcome rankings (DOOR), were compared between patients infected with isolates not susceptible vs susceptible to each agent. Of 800 CRPA isolates, susceptibility to C/T, CZA, and I/R was 69%, 67%, and 33%, respectively. USA isolates ( n = 526) were more frequently susceptible to these agents than isolates from other countries ( n = 274; C/T: 83% vs 42%; CZA: 77% vs 47%; I/R: 37% vs 23%; P < 0.001 for each comparison) and isolates with carbapenemases ( n = 157) were less frequently susceptible than isolates without carbapenemases ( n = 643; C/T: 7% vs 84%; CZA: 24% vs 77%; I/R: 6% vs 39%; P < 0.001 for each comparison). Thirty-day mortality and DOOR were similar overall in patients infected with isolates not susceptible vs susceptible to each βL/βLI. However, the adjusted probability of a better DOOR outcome for a randomly selected patient with bacteremia due to a C/T-not susceptible vs -susceptible isolate was 38.2% (95% confidence interval, 25.6%–52.7%). Resistance to novel βL/βLIs, especially I/R, is common in CRPA, particularly outside the USA and in carbapenemase-producing isolates. Additional treatment options are needed for CRPA infections.